What would you do if your brand could no longer advertise on TV?
For thirty years, the loudest brand won. That era is ending.
Aaron Uydess
Independent Principal & Founder
Key takeaways
Proposed FDA and HHS rules, and the Responsibility in Drug Advertising Act, threaten the 60-second TV drug ad.
Connected TV and branded short-form social inherit the same disclosure burden. Unbranded education is where social earns its place.
Brands with findable patients, like Vertex in cystic fibrosis, can win without TV. Build first-party data and measurement now.
The disruption everyone fears is the best opening the underdogs have had in a generation.
Years ago, during annual brand planning while working in pharma and leading a COE, an executive asked a question I’ve never forgotten: without changing the revenue goals and spend, how would this brand survive the elimination of DTC advertising in general or TV only?
It was a thought experiment with low odds, and that was the point. It attacked what we all took as a given: that you buy reach to drive revenue at scale, and that the biggest reach channel was just part of the furniture. Take it away, keep the number, and every comfortable assumption is back on the table. I found it intriguing then. It is no longer hypothetical now.
For almost thirty years, pharma marketing ran on a simple, unfair rule: the brand with the biggest broadcast budget won the patient. If you couldn’t afford a Super Bowl spot, you weren’t really in the conversation. That rule is cracking. If you run a smaller or emerging brand, you should be the first to cheer.
What’s breaking
The US is one of only two countries that allow DTC prescription advertising,[1] and more than $10.1 billion a year flows into it.[2] The entire 60-second TV spot rests on one mechanism: broadcast ads state only the major risks aloud and point you elsewhere for the rest. That trade-off, in place since the late 1990s, is why drug ads are watchable.
In September 2025, FDA and HHS moved to take it away.[3] By the agencies’ own admission, a spot reading every contraindication would run minutes, not seconds. Before this mechanism existed, broadcast drug ads were rare for exactly that reason. This is not a tweak. It is a question of whether the format survives.
And it is two fronts, not one. In Congress, the Responsibility in Drug Advertising Act would bar DTC for a new drug’s first three years on the market.[4] Both efforts face First Amendment headwinds and may not pass. But the intent is clear, and intent is what you plan against: HHS now blames DTC for roughly 31% of the rise in drug spending since 1997.[5]
So here is the provocative part. The most exposed brands aren’t the small ones. They’re the giants: the blockbuster franchises with hundreds of millions in TV spend, the most inertia to unwind, and agencies built around a channel going dark. Their megaphone is breaking.
The void won’t be filled by better TV
Every brand reaches for the nearest substitute: connected TV, streaming, social, influencer. Most miss the point. The same 2025 action named “closing digital loopholes” and social media oversight.[6] CTV gives sharper targeting but inherits the disclosure burden breaking broadcast.
Short-form is the real trap. A Reel, a TikTok, a YouTube Short is built for seconds, sound on, thumb already moving. You cannot fit a major-risk statement into fifteen vertical seconds without killing the thing that makes it work. The format that looks most like cheap scale is the one you can least use for a branded claim. Branded social is not the escape hatch. It is the next room the squeeze walks into.
Where social earns its place is the one job that doesn’t trip the rules: unbranded education. Disease awareness, patient community, help-seeking content that never pairs a drug name with a claim carries no fair-balance burden, because it isn’t a drug ad. Use social to build demand you can actually capture. Don’t ask it to make the claim TV used to make for you.
But can the math still work?
The question your CFO asks first. Look at Vertex. Its cystic fibrosis franchise drove $11.02 billion in 2024, with Trikafta alone at $8.9 billion the year before, on essentially no consumer TV.[7] The CF population is small and identifiable. When a label expansion adds a few hundred eligible patients, you don’t buy a Super Bowl to find them. You reach them through specialists, advocacy, and patient support. Precision, not reach.
So the honest answer is another question: how findable is your patient? The more identifiable they are, the easier broadcast is to replace and the better your return without it. That names the seam in my own headline: yes, the three-year rule targets new launches, and emerging brands are new launches. But a brand whose patient is findable never needed the broadcast launch the rule takes away.
Now what
The rulemaking will take a year or more, with comment periods and a constitutional fight. That is not a reason to wait. It is your opportunity. Build first-party data, stand up unbranded education, deepen point of care, and fix your measurement: the no-regrets moves that pay off however the rule lands. The brand that can’t measure impact will panic when broadcast wobbles. The one that can will arbitrage the disruption while the giants are still in meetings.
For thirty years the rule favored the big. The new one favors the brand closest to the patient, that owns its relationships, and won’t confuse being loud with being effective. That was never the giants. It was always you.
The brands that map their options are the ones still standing when the changes happen.
CONTACT US TODAY
The first conversation is twenty-five minutes — a diagnostic, not a pitch. Pick a time with Aaron below, or send us a note about what you’re working on.
About Kairos Meridian
Kairos Meridian provides pharma strategy, marketing, and analytics in service of impact… with a dose of innovation. We serve as the senior, independent partner for pharma brands, for vendors that sell into them, and for the private equity firms making decisions about pharma-related assets.
Kairos Meridian, where strategy meets the moment, provides big agency thinking with boutique agility. We serve as strategist, operator and the additional arms & legs our clients need to hit and exceed goals.
Tagged
Patient
TV
Video
DTC
DTP
FAQ
Have questions?
Check out the FAQs
What is Kairos Meridian?
Kairos Meridian is a next generation independent pharma commercial strategy consultancy based in New Jersey. Founded by Aaron Uydess, it gives senior, partner-led counsel to small and mid-cap pharma and biotech brands, the vendors that sell to them, and private equity firms holding pharma assets. Its work covers commercial strategy, omnichannel, direct-to-patient (DTP), data and analytics, and AI. It sells no technology or media.
Who founded Kairos Meridian, and what is their background?
Aaron Uydess founded Kairos Meridian in 2026. He has 25+ years in life sciences commercial strategy in the U.S. and abroad. He worked client-side at Novo Nordisk and BMS and agency-side at INTOUCH Group and EVERSANA. His work spans brand strategy, digital marketing, data and analytics, omnichannel activation, DTP and applied AI.
Is Kairos Meridian a good fit for an emerging pharma brand preparing for launch?
Yes. Kairos Meridian is built for small and mid-cap brands from 12–18 months before launch through their first five years on market. It works three ways: The Devil's Advocate pressure-tests the launch plan, The Consigliere advises through the launch, and The Partner by Mandate embeds as senior commercial leadership. It doesn't buy media, produce campaigns or implement platforms, so it works alongside your agencies.
How does Kairos Meridian compare to ZS, IQVIA and the big consulting firms?
Kairos Meridian is a senior, partner-led consultancy; ZS, IQVIA, McKinsey and Deloitte are large firms. They bring scale, deep benches and proprietary data or software, and strategy work often leads into a platform or implementation sale. Kairos Meridian has no platform, data product or media to sell. It's sized for emerging brands and mid-market deals that need a senior voice in the room, not a project team.
How does Kairos Meridian price its consulting engagements?
Every engagement is a fixed fee, scoped to the question and the weight of the answer. That holds for all three offerings, from a single-decision review to an embedded mandate. Kairos Meridian doesn't bill by the hour, by the day, by headcount or with agency overhead. It takes no commissions, markups, referral fees or equity from clients. Fees aren't published; the first step is a 25-minute diagnostic.
Who does Kairos Meridian work with?
Kairos Meridian works with three groups: small and mid-cap pharma and biotech brands in their first five years, the agencies and technology and data vendors selling into them, and private equity firms investing in pharma and pharma-adjacent assets. Its founder's experience spans 5+ pharma companies, 10+ brands and 5+ therapeutic areas.
How does Kairos Meridian stay independent?
Independence is built into how the firm runs. Kairos Meridian isn't part of an agency network or holding company. It won't advise both sides of a deal or competing bids, accept payment from vendors to be recommended, or take equity in a client's outcome. When it suggests execution partners, it offers a slate and discloses its relationship with each.
Is Kairos Meridian an agency or a fractional executive firm?
Neither. Kairos Meridian is a consultancy. It doesn't buy media, make creative or run campaigns, as an agency would. It isn't a fractional executive network either: fractional arrangements sell a share of someone's time, while Kairos Meridian takes interim leadership roles against a written mandate with a defined goal and an end date.
Is Kairos Meridian connected to kairosmeridian.com?
No. Kairos Meridian LLC, the pharma commercial strategy consultancy founded by Aaron Uydess, is at kairosmeridian.us. The site at kairosmeridian.com belongs to an unrelated business with a similar name. Kairos Meridian has no market research, investment research or private equity intelligence products.
The first conversation is twenty-five minutes — a diagnostic, not a pitch.
Start a conversation today
We listen for the real problem — how you got here, what you’ve tried, what success looks like — then come back with a structured read. The gap between the call and the response is where the senior judgment gets applied.